News Breaks |
|
|
| December 9, 2012 |
| 16:45 EDT |  | SNY | Sanofi Phase II trial of Sanofi JAK2 inhibitor in MF met primary endpoint
Sanofi announced new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis, MF, a hematologic malignancy with unmet medical needs. The data were presented during the 2012 Annual Meeting of the American Society of Hematology in Atlanta, Ga., December 8-11. |
|
|
News For SNY From The Last 14 Days Check below for free stories on SNY the last two weeks. |
|
|
| May 17, 2013 |
| 08:03 EDT | | SNY | Sanofi reports positive topline results from pivotal Phase III Jakarta study
 Subscribe for More Information |
|
| 05:18 EDT | | SNY | Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint
Subscribe for More Information |
|
| May 15, 2013 |
| 15:16 EDT | | SNY | Sanofi systemic sclerosis treatment designated for orphan drug status
Subscribe for More Information |
|
| 05:39 EDT | | SNY | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 13, 2013 |
| 09:44 EDT |  | SNY | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:30 EDT |  | SNY | TechConnect to host a summit
2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
|
| May 10, 2013 |
| 11:48 EDT | | SNY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| May 6, 2013 |
| 07:49 EDT | | SNY | Bernstein's global pharmaceuticals analyst has analyst/industry conference call
Subscribe for More Information |
|
|
|
|
|
